Europe Epilepsy Drugs Market Size & Outlook, 2025-2030
Related Markets
Europe epilepsy drugs market highlights
- The Europe epilepsy drugs market generated a revenue of USD 3,166.9 million in 2024.
- The market is expected to grow at a CAGR of 4.8% from 2025 to 2030.
- In terms of segment, first generation anti-epileptics was the largest revenue generating product in 2024.
- Second Generation Anti-epileptics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 3,166.9 million |
| Market revenue in 2030 | USD 4,185.1 million |
| Growth rate | 4.8% (CAGR from 2025 to 2030) |
| Largest segment | First generation anti-epileptics |
| Fastest growing segment | Second Generation Anti-epileptics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics |
| Key market players worldwide | UCB SA, Sanofi SA, Pfizer Inc, Otsuka Pharmaceutical, Eisai Co Ltd, Abbott Laboratories, Novartis AG ADR, GlaxoSmithKline, Sumitomo Pharma Co Ltd, Neurelis, Jazz Pharmaceuticals PLC |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.4% of the global epilepsy drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,181.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Epilepsy Drugs Market Scope
Epilepsy Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | View profile | 2800 | Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, Ireland, D04 E5W7 | https://www.jazzpharmaceuticals.com |
| Sumitomo Pharma Co Ltd | View profile | 6250 | 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Japan, 541-0045 | https://www.sumitomo-pharma.com |
| Neurelis | View profile | 101-250 | Encinitas, California, United States, North America | http://www.neurelis.com/ |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Eisai Co Ltd | View profile | 11076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | http://www.eisai.co.jp |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Europe epilepsy drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epilepsy drugs market will help companies and investors design strategic landscapes.
First generation anti-epileptics was the largest segment with a revenue share of 41.56% in 2024. Horizon Databook has segmented the Europe epilepsy drugs market based on first generation anti-epileptics, second generation anti-epileptics, third generation anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe epilepsy drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe epilepsy drugs market databook
-
Our clientele includes a mix of epilepsy drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe epilepsy drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe epilepsy drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe epilepsy drugs market size, by country, 2018-2030 (US$M)
Europe Epilepsy Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
